ENLV
Enlivex Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.09 / 10
Netural
With a fund flow rating of 7.88/10, the stock shows robust fund flow characteristics. Supportive momentum from overall, block, Small, Medium, Large, and Extra-large trends is partially offset by concerning no significant trends patterns, pointing to positive capital flow trajectory. Analyst coverage indicates overwhelmingly bullish analyst consensus with strong conviction. Rating distribution: Strong Buy(100.0%) among 1 analysts, supported by 2.31 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-12
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate33.3%
Is money flowing into or out of ENLV?
- ENLV holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.09/10 (Netural).
